The time reported for biopharmas to develop a drug from the Discovery phase through Pre-clinical and Clinical trial phases and FDA submission is 10 to15 years. In that process the “Discovery” phase takes roughly half of that time, as thousands to tens of thousands of candidate compounds are generally evaluated for a specific application using conventional means. This current process reduces the candidate compounds to the few hundred that are selected for Pre-clinical testing and the 5 or so of those that are moved on to Clinical trials. From this entire process one compound is submitted to the FDA for approval for that application.
The AcPET system can dramatically accelerate the Discovery phase of drug development by using its proprietary DNA library. Within the over 100 trillion DNA codes in the DNA library are codes for the few proteins that meet the requirements for the specific application being addressed. The AcPET system converts the 100 trillion DNA codes to 100 trillion proteins, each linked to their specific mRNA code. This huge library of protein-mRNA complexes are reduced to a few protein candidates in a couple days by reacting the entire 100 trillion protein-mRNA complexes with the target of interest. From this only one, or very few, proteins will react and bind with the target of interest. Those candidates are then isolated for further development. As such, the AcPET system has the potential to lower the Discovery phase bottleneck of drug development from years to a few weeks, a huge cost savings for the biopharma industry and a huge asset to patients in need of new drugs to treat disease.
Human Pharmaceuticals
The AcPET system can be used to make recombinant proteins for virtually any purpose where monoclonal antibodies (mAb) are currently being used, but without the development cost in time and dollars or the patent infringement issues of mAbs.